Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study

Fig. 2

Baseline serum cytokine concentrations in patients who achieved DAPSA-REM and not. Data are presented as median (IQR). A Differences in serum cytokine concentrations in patients treated with IL-17-i between patients with DAPSA-REM (n=11) and those without (non) (n=12). B Comparison of serum cytokine concentrations in patients treated with TNF-i between patients with DAPSA-REM (n=12) and those without (non) (n=12). *p <0.05, Mann-Whitney U test

Back to article page